PHARMACIA DIAGNOSTICS AB – Trademark Portfolio
Entity Type: 03
PHARMACIA DIAGNOSTICS AB holds 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 7 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 4 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include PHADEBACT. The owner is based in UPPSALA.
SE-751 82
UPPSALA , SE
Showing of trademarks Trademarks
Trademark Classifications
PHARMACIA DIAGNOSTICS AB's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does PHARMACIA DIAGNOSTICS AB have?
PHARMACIA DIAGNOSTICS AB has 11 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 abandoned, 7 cancelled.
What trademark classes does PHARMACIA DIAGNOSTICS AB file in?
PHARMACIA DIAGNOSTICS AB files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 10 (Medical Apparatus), Class 9 (Computers & Electronics). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are PHARMACIA DIAGNOSTICS AB's most well-known trademarks?
PHARMACIA DIAGNOSTICS AB's registered trademark portfolio includes well-known marks such as PHADEBACT. These are among 1 currently registered trademark in the portfolio.
What is PHARMACIA DIAGNOSTICS AB's trademark registration success rate?
PHARMACIA DIAGNOSTICS AB has a 10% trademark registration rate, with 1 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.